1. Home
  2. BEAM vs IIPR Comparison

BEAM vs IIPR Comparison

Compare BEAM & IIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • IIPR
  • Stock Information
  • Founded
  • BEAM 2017
  • IIPR 2016
  • Country
  • BEAM United States
  • IIPR United States
  • Employees
  • BEAM N/A
  • IIPR N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • IIPR Real Estate
  • Sector
  • BEAM Health Care
  • IIPR Finance
  • Exchange
  • BEAM Nasdaq
  • IIPR Nasdaq
  • Market Cap
  • BEAM 1.6B
  • IIPR 1.5B
  • IPO Year
  • BEAM 2020
  • IIPR 2016
  • Fundamental
  • Price
  • BEAM $19.88
  • IIPR $57.04
  • Analyst Decision
  • BEAM Strong Buy
  • IIPR Hold
  • Analyst Count
  • BEAM 11
  • IIPR 8
  • Target Price
  • BEAM $48.90
  • IIPR $88.75
  • AVG Volume (30 Days)
  • BEAM 2.0M
  • IIPR 259.2K
  • Earning Date
  • BEAM 08-05-2025
  • IIPR 08-04-2025
  • Dividend Yield
  • BEAM N/A
  • IIPR 13.32%
  • EPS Growth
  • BEAM N/A
  • IIPR N/A
  • EPS
  • BEAM N/A
  • IIPR 5.20
  • Revenue
  • BEAM $63,578,000.00
  • IIPR $304,785,000.00
  • Revenue This Year
  • BEAM N/A
  • IIPR N/A
  • Revenue Next Year
  • BEAM $8.82
  • IIPR $0.94
  • P/E Ratio
  • BEAM N/A
  • IIPR $10.98
  • Revenue Growth
  • BEAM N/A
  • IIPR N/A
  • 52 Week Low
  • BEAM $13.53
  • IIPR $45.44
  • 52 Week High
  • BEAM $35.25
  • IIPR $138.35
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 67.72
  • IIPR 51.64
  • Support Level
  • BEAM $16.59
  • IIPR $54.22
  • Resistance Level
  • BEAM $17.38
  • IIPR $57.62
  • Average True Range (ATR)
  • BEAM 1.09
  • IIPR 1.55
  • MACD
  • BEAM 0.24
  • IIPR -0.14
  • Stochastic Oscillator
  • BEAM 93.78
  • IIPR 53.41

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About IIPR Innovative Industrial Properties Inc.

Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.

Share on Social Networks: